StockData
CEROOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as CEROW

CERO THERAPEUTICS HOLDINGS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.01+0.00 (0.00%)

Close on Oct 19, 2026

Market cap
$253.05K
P/E (TTM)
–
Dividend yield
172833.33%

CERO THERAPEUTICS HOLDINGS, INC. revenue by segment

No segment breakdown reported

Cero Therapeutics does not break out revenue by segment, region or product in the tagged data of its filings for this period type.